MX2020010425A - Composicion isotopicamente modificada y sus usos terapeuticos. - Google Patents

Composicion isotopicamente modificada y sus usos terapeuticos.

Info

Publication number
MX2020010425A
MX2020010425A MX2020010425A MX2020010425A MX2020010425A MX 2020010425 A MX2020010425 A MX 2020010425A MX 2020010425 A MX2020010425 A MX 2020010425A MX 2020010425 A MX2020010425 A MX 2020010425A MX 2020010425 A MX2020010425 A MX 2020010425A
Authority
MX
Mexico
Prior art keywords
therapeutic uses
isotopically modified
modified composition
isotopically
ester
Prior art date
Application number
MX2020010425A
Other languages
English (en)
Inventor
Mikhail Sergeevich Shchepinov
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Publication of MX2020010425A publication Critical patent/MX2020010425A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga un ácido graso poliinsaturado modificado isotópicamente o uno de sus ésteres, como el ácido 11,11-D2 linoleico o su éster etílico, así como su uso para el tratamiento o mitigación de los síntomas de la ataxia de Friedreich.
MX2020010425A 2018-04-04 2019-04-03 Composicion isotopicamente modificada y sus usos terapeuticos. MX2020010425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652855P 2018-04-04 2018-04-04
PCT/US2019/025646 WO2019195467A1 (en) 2018-04-04 2019-04-03 Isotopically modified composition and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2020010425A true MX2020010425A (es) 2021-03-09

Family

ID=68101517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010425A MX2020010425A (es) 2018-04-04 2019-04-03 Composicion isotopicamente modificada y sus usos terapeuticos.

Country Status (6)

Country Link
US (2) US20210069144A1 (es)
EP (1) EP3773541A4 (es)
AU (1) AU2019247762A1 (es)
CA (1) CA3096035A1 (es)
MX (1) MX2020010425A (es)
WO (1) WO2019195467A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2023158641A1 (en) * 2022-02-15 2023-08-24 Retrotope, Inc. Synergistic combination therapy for treating als

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604647D0 (en) * 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
US10052299B2 (en) * 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
US10154978B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
WO2012148926A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
EP3730135A1 (en) * 2011-04-26 2020-10-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
WO2017037567A1 (en) * 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
US10730821B2 (en) * 2015-11-23 2020-08-04 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems

Also Published As

Publication number Publication date
US20210069144A1 (en) 2021-03-11
WO2019195467A1 (en) 2019-10-10
US20240238238A1 (en) 2024-07-18
AU2019247762A1 (en) 2020-10-15
EP3773541A4 (en) 2022-01-05
EP3773541A1 (en) 2021-02-17
CA3096035A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018502634A1 (en) Topical compositions of apremilast
MX2020013853A (es) Compuestos innovadores.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
MX2018010395A (es) Formulaciones topicas que contienen cliclosporina y usos de las mismas.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2020010425A (es) Composicion isotopicamente modificada y sus usos terapeuticos.
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
MX2021009825A (es) Suplemento alimenticio.